Literature DB >> 15552528

Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus.

J J Cush1.   

Abstract

Serious and unexpected adverse events, such as heart failure and drug-induced lupus, have been reported in patients receiving TNF inhibitor therapy. These events generally are easily recognizable, although they cannot be predicted nor avoided, other than by drug avoidance altogether Many patients have great benefit from anti-TNF therapies. Their intelligent use requires a firm understanding of these rare toxicities, so as to minimize the morbidity associated with their uncommon occurrence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15552528

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  14 in total

1.  Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment.

Authors:  Ismail Sari; Merih Birlik; Can Gonen; Servet Akar; Duygu Gurel; Fatos Onen; Nurullah Akkoc
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 2.  A Practical Guide to the Safety and Monitoring of New IBD Therapies.

Authors:  Benjamin Click; Miguel Regueiro
Journal:  Inflamm Bowel Dis       Date:  2019-04-11       Impact factor: 5.325

3.  Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.

Authors:  David A Wetter; Mark D P Davis
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 4.  A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?

Authors:  Tânia Santiago; Mariana Galante Santiago; João Rovisco; Cátia Duarte; Armando Malcata; José António Pereira da Silva
Journal:  Clin Rheumatol       Date:  2013-08-17       Impact factor: 2.980

5.  Tumor necrosis factor-alpha prevents desensitization of Galphas-coupled receptors by regulating GRK2 association with the plasma membrane.

Authors:  Nguyen D Khoa; Michael Postow; Jennifer Danielsson; Bruce N Cronstein
Journal:  Mol Pharmacol       Date:  2005-12-29       Impact factor: 4.436

Review 6.  Therapeutic anti-integrin (alpha4 and alphaL) monoclonal antibodies: two-edged swords?

Authors:  Roberto González-Amaro; María Mittelbrunn; Francisco Sánchez-Madrid
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

Review 7.  How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets.

Authors:  Virginia Pascual; Florence Allantaz; Pinakeen Patel; A Karolina Palucka; Damien Chaussabel; Jacques Banchereau
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

8.  Atypical infectious mononucleosis in a patient receiving tumor necrosis factor alpha inhibitory treatment.

Authors:  Ismail Sari; Merih Birlik; Servet Akar; Fatos Onen; Aydanur Kargi; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2008-11-26       Impact factor: 2.631

9.  Tumor necrosis factor-α promotes and exacerbates calcification in heart valve myofibroblast populations.

Authors:  Andrea Gonzalez Rodriguez; Megan E Schroeder; Joseph C Grim; Cierra J Walker; Kelly F Speckl; Robert M Weiss; Kristi S Anseth
Journal:  FASEB J       Date:  2021-03       Impact factor: 5.834

10.  Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus().

Authors:  Hani Almoallim; Yahya Al-Ghamdi; Haneen Almaghrabi; Omnia Alyasi
Journal:  Open Rheumatol J       Date:  2012-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.